The most prevalent asthma phenotype is allergic asthma, which is primarily a chronic inflammatory illness characterized by increased serum IgE levels and specific-IgE against common allergens. Despite the use of medium/high dosages of inhaled corticosteroids (ICS) in conjunction with another controller, a substantial number of asthmatic children have uncontrolled moderate/severe symptoms. In these children, asthma guidelines recommend omalizumab as an add-on treatment, and new data has demonstrated the effectiveness and safety of this mAb against IgE. Asthma cannot be cured, and existing therapies are unable to alter the disease’s natural path. Recent research has found that omalizumab can help reduce airway inflammation and remodeling. A 4-year follow-up of a group of children with moderate/severe uncontrolled asthma who participated in a randomized double-blind placebo-controlled trial with omalizumab is presented below. Children were monitored for four years after the anti-IgE treatment was discontinued. They were entirely free of asthma symptoms for the first three years of follow-up, with no need for ICS or rescue medicine.

The fresh facts and clinical observation reported herein support the idea that omalizumab therapy might potentially alter the normal course of asthma. However, more research is required.